|1.||London, Cheryl A: 3 articles (01/2015 - 12/2009)|
|2.||Ying, Weiwen: 2 articles (01/2011 - 12/2009)|
|3.||Foley, Kevin P: 2 articles (01/2011 - 12/2009)|
|4.||Bear, Misty D: 2 articles (01/2011 - 12/2009)|
|5.||Barsoum, James: 2 articles (01/2011 - 12/2009)|
|6.||Lorch, Gwendolen: 1 article (01/2015)|
|7.||Clemente-Vicario, Francisco: 1 article (01/2015)|
|8.||Rowell, Jennie L: 1 article (01/2015)|
|9.||Alvarez, Carlos E: 1 article (01/2015)|
|10.||Kisseberth, William C: 1 article (01/2015)|
01/01/2011 - "The purpose of the following study was to extend these observations and investigate the safety and efficacy of STA-1474 in dogs with spontaneous tumors. "
01/01/2011 - "This study provides evidence that STA-1474 exhibits biologic activity in a relevant large animal model of cancer. "
01/01/2011 - "This was a Phase 1 trial in which dogs with spontaneous tumors received STA-1474 under one of three different dosing schemes. "
01/01/2015 - "Treatment of tumor-stromal fibroblasts with STA-1474 resulted in a dose-dependent decrease in their relative cell viability with a low IC50 of 0.28 μM. "
01/01/2011 - "Given the similarities of canine and human cancers with respect to tumor biology and HSP90 activation, it is likely that STA-1474 and ganetespib will demonstrate comparable anti-cancer activity in human patients."
|2.||Lung Neoplasms (Lung Cancer)
01/01/2015 - "As significant decreases in relative cell viability can be achieved with nanomolar concentrations of STA-1474, investigation into the clinical efficacy of this drug in canine lung cancer patients is warranted."
01/01/2015 - "We investigated the activity of STA-1474, a HSP90 inhibitor, in two canine lung cancer cell lines, BACA and CLAC. "
|3.||Osteosarcoma (Osteogenic Sarcoma)
|1.||Caspase 3 (Caspase-3)
|1.||Heterologous Transplantation (Xenotransplantation)